Helus Pharma Inc. (HELP) Form 6-K — Oct 15, 2026

$HELPForm 6-KFiled Oct 15, 2026, 9:32 AM ET0001833141-26-000091Original filing

Helus Pharma (Nasdaq: HELP) appointed Dr. Suresh Durgam to its Board of Directors, announced October 15, 2026. Dr. Durgam was previously EVP and Chief Medical Officer of Intra-Cellular Therapies (acquired by Johnson & Johnson in April 2025) and played a pivotal role in securing FDA approvals for CAPLYTA across multiple indications.

AI analysis

Red flags2 · Pro

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

Upgrade to Pro · $40.67/mo billed annually

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.